-transparent.png){kind=logo}
Forty-six patients who were treated with cisplatin or carboplatin for ovarian cancer developed resistant disease (no change in measurable disease or progressive disease) and 'crossed over' to the other platinum compound. Three patients (6.5%) responded to this second treatment but these patients had no survival advantage compared to the non-responders. One responder had progressive disease on cisplatin before crossing over to carboplatin.
Related Publications
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
October 1995,
Seminars in oncology,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
January 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
August 1994,
Drug and therapeutics bulletin,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
January 2010,
Genes, chromosomes & cancer,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
November 1990,
Gynecologic oncology,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
April 1994,
Seminars in oncology,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
February 1992,
Seminars in oncology,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
October 1989,
Journal of the National Cancer Institute,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
January 2000,
Gynecologic and obstetric investigation,
M E Gore, and
I Fryatt, and
E Wiltshaw, and
T Dawson, and
B A Robinson, and
A H Calvert
November 1993,
Gynecologic oncology,
